Case Report

Auto-Administered Photobiomodulation on Diabetic Leg Ulcers Treatment: A New Way to Manage It?

Elisabetta Merigo, Lixin Tan, Zengyi Zhao, Jean-Paul Rocca, and Carlo Fornaini

1Faculty of Dentistry, University "Côte d’Azur", 5 Avenue du 22ème BCA, 06357 Nice, France
2Department of Diabetes, 2nd Hospital, Gongnong Road 425, Shijiazhuang, Hebei Province, China
3Department of Stomatology, 2nd Hospital, Gongnong Road 425, Shijiazhuang, Hebei Province, China
4GAEM Group of Applied Electro Magnetics, Department of Engineering and Architecture, University of Parma, Viale G. P. Usberti 181/A-43124, Parma, Italy

Correspondence should be addressed to Elisabetta Merigo; elisabetta.merigo@gmail.com

Received 8 January 2020; Revised 15 April 2020; Accepted 1 May 2020; Published 21 May 2020

Academic Editor: Georgios D. Kotzalidis

Background. Peripheral arterial disease is a dramatic consequence of an uncontrolled diabetic condition causing an increase of morbidity and mortality and its treatment is currently medical or surgical, finally requiring, in the 7–20% of cases, major or minor amputation. Photobiomodulation therapy (PBM) is a laser treatment used in medicine, thanks to its ability to stimulate the wound healing, the acceleration of inflammatory process, and the modulation of pain. Its use in the treatment of diabetic foot ulcers has been recently reported by several studies: Li et al., in their meta-analysis paper, described the usefulness of PBM in treating diabetic foot ulcers in order to improve healing rate, reduce ulcer diameter, and relieve pain, by using wavelengths of 400–904 nm with a fluence of 2–10 J/cm² [7], while Maya et al. suggested the use of a wavelength of 632.8 nm and a fluence of 3.1 J/cm² [8]. Mathur et al. highlighted the use of

1. Introduction

Peripheral arterial disease is one of the main consequences of an uncontrolled diabetic condition and also the main cause of ulcers leading to the so-called diabetic foot ulcers (DFU) and diabetic leg ulcers (DLU), which are a complication affecting about 15% of the diabetic patients [1, 2] and causing an increase of morbidity and mortality [3]. The treatment of this disease is currently medical, by means of a broad-spectrum antibiotic therapy, or surgical, finally requiring, in the 7–20% of cases, major amputation (leg or thigh) or minor amputation (toes or foot), being both procedures at risk of mortality [3–5].
660 nm laser at a fluence of 3 J/cm² with similar positive results [9].

Tantawy et al. compared, in addition to conventional therapy, He-Ne laser (wavelength of 632 nm) PBM performed during 90 seconds with a fluence of 5 J/cm² and 904 nm diode PBM performed at 25 Hz for 90 seconds with a fluence of 6 J/cm² and found a significant reduction in ulcers surface without statistically significant difference between the 2 laser devices used [10].

Recently, the “at-home PBM” treatment has been suggested for different purposes in medicine and dentistry. It is based on self-administration of the treatment by the patient with a great number of advantages and no side effects [11–13].

The aim of this work is to show the possibility to use, in the treatment of ulcers in diabetic foot/leg, this new laser device recently proposed in the market.

2. Case Report

A 84-year-old Chinese woman, affected by diabetes type 2 from 32 years and positive for diabetes complications such as eye disease, nephropathy, neuropathy, and vascular disease, was evaluated for a routine control by her diabetologist. She was under insulin treatment and her blood sugar balance was acceptable. During the visit, the doctor noticed, probably due to the itchy skin, the presence of painful ulcerative lesions (the biggest one of 1 cm diameter) on the lowest part of the right leg (Figure 1), which the patient described as appeared for at least 3 weeks.

The same day, the patient, after giving her informed consent about the treatment and also allowing the publication of the pictures, started the treatment on the lesions applying B-Cure Laser Pro (Erika Carmel, Haifa, Israel) on her own. This device (Figure 2) emits in the infrared spectrum (808 nm) with a green LED aiming beam indicating the irradiation area, which is an elliptic shape with the two axes measuring 45 and 10 mm for a total surface of 4.5 cm². It was not necessary, for the patients, to wear protective glasses because the appliance used is classified as class I device by the American National Standard Institute.

When applied in contact to the target tissue, out-performed plastic allows to maintain the beam at a distance of 10 mm. In this way, it is able to deliver to the tissues an output power of 250 mW (55.5 mW/cm²) emitted in micropulses with a frequency of 15 kHz, for an energy per minute of 14.4 Joules and a fluence per minute of 3.2 J/cm².

Treatment was daily performed for 2 sessions of 15 minutes (total fluence 48 J/cm²) by cutaneous application (Figure 3); after a week of treatment, the smallest ulcers (upper and right lower) dried and crusted (Figure 4) and the largest one (lower) had a significant improvement. Finally, all the ulcers got completed healed after 30 days of treatment (Figure 5).

3. Discussion

The use of self-administered laser PBM in this case of ulcerative lesions related to diabetes disease gained an interesting result in terms of healing. Results described for this case report are related to mechanisms of laser PBM as the promotion of physiological effects such as keratinocyte and fibroblast proliferation, maturation and migration, collagen synthesis and deposition, activation of macrophages, and overall in DFU/DLU endothelial cell proliferation, neoangiogenesis and revascularization [6]. The choice of the wavelength of 808 nm was supported by previous reports in the literature describing evidence for the
stimulation effects particularly on endothelial cells. Amaroli et al. in 2019 described effects in wound healing repair for treatment performed with an 808 nm laser at a fluence of 60 J/cm² [14].

Diabetes is a disease with a high impact on a population in terms of prevalence, incidence, and morbidity, and diabetic foot ulcers is one of its most important consequences with very severe difficulties in its management and treatment and with devastating consequences for the patients in terms of quality of life.

Diabetic foot ulcers and diabetic leg ulcers are complications with a high impact in terms of morbidity, mortality, and healthcare costs, involving, as reported by the International Diabetes Federation, between 9.1 and 26.1 million people with a 5% mortality in the first 12 months and a 42% mortality within 5 years [14].

Actually, standard care includes local wound care with surgical debridement, dressings promoting a moist wound environment, wound off-loading, vascular assessment, treatment of active infection, and glycemic control with an estimated cost of US $176 billion (report 2012) but unfortunately also with a 20% of patients have unhealed at 1 year [15].

The protocol described may obtain good results in terms of pain control and patient compliance. PBM therapy is a noninvasive therapy already described as useful for the management of this complication; unfortunately, the limiting factor of this kind of treatment consists on the needing, for the patients, to go to the therapist at least twice/three times weekly for treatments of some minutes, and this factor may negatively influence the compliance of the patient toward the therapy.

Due to the reduced size and the belonging to the class I laser according to the ANSI classification, of the “at-home PBM” laser device, it may be self-administered at home by the patient, and this represents a great and innovative possibility to manage the treatment of this kind of diseases. The availability on the market of these new, cheap, small, and usable at home by the patients themselves PBM appliances might be included in standard therapy for this kind of problem, giving the possibility to the patients to receive PBM treatment also daily; having the patient only a time setting as part of the device, the danger of over treating is reduced.

4. Conclusion

At-home PBM therapy is a new chapter of the laser medicine, which was born when new small appliances able to be used by patients themselves appeared in the market. More and more fields of utilization were proposed in these last years, and by means of this short case report, we think to add a further contribution by suggesting this kind of treatment for successful management of the foot ulcers in diabetic patients and encouraging research development to improve the strength of evidence for this application.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

References

[1] G. Vicenti, D. Bizzoca, I. Caruso et al., “New insights into the treatment of non-healing diabetic foot ulcers,” Journal of Biological Regulators and Homeostatic Agents, vol. 32, no. 6 Suppl. 1, pp. 15–21, 2018.
[2] S. C. Mishra, K. C. Chhatbar, A. Kashikar, and A. Mehndiratta, “Diabetic foot,” BMJ, vol. 359, Article ID j5064, 2017.
[3] E. L. Gouta, M. Khalfallah, W. Dougaz et al., “Morbidity and mortality of infected diabetic foot managed in general surgical department,” La Tunisie Medecale, vol. 96, no. 12, pp. 875–883, 2018.
[4] J. de Alencar Fonseca Santos, M. B. D. Campelo, R. A. de Oliveira, R. A. Nicolau, V. E. A. Rezende, and E. A. L. Arisawa, “Effects of low-power light therapy on the tissue repair process of chronic wounds in diabetic feet,” Photomedicine and Laser Surgery, vol. 36, no. 6, pp. 298–304, 2018.
[5] L. M. A. Dutra, M. C. Melo, M. C. Moura et al., “Prognosis of the outcome of severe diabetic foot ulcers with multidisciplinary care,” Journal of Multidisciplinary Healthcare, vol. 12, pp. 349–359, 2019.
[6] E. Merigo, J. -P. Roca, A. L. B. Pinheiro, C. Fornaini, and C. Fornaini, “Photobiomodulation therapy in oral medicine: a guide for the practitioner with focus on new possible protocols,” Photobiomodulation, Photomedicine, and Laser Surgery, vol. 37, no. 11, pp. 669–680, 2019.

Figure 4: Clinical appearance after a week of treatment: the smallest ulcers (upper and right lower) dried and crusted, and the largest one (lower) achieved a significant improvement.

Figure 5: Complete healing of all the lesions after 30 days of the laser treatment.
[7] S. Li, C. Wang, B. Wang et al., “Efficacy of low-level light therapy for treatment of diabetic foot ulcer: a systematic review and meta-analysis of randomized controlled trials,” *Diabetes Research and Clinical Practice*, vol. 143, pp. 215–224, 2018.

[8] A. G. Maiya, A. S. Kumar, A. Hazari et al., “Photobiomodulation therapy in neuroischaemic diabetic foot ulcers: a novel method of limb salvage,” *Journal of Wound Care*, vol. 27, no. 12, pp. 837–842, 2018.

[9] R. K. Mathur, K. Sahu, S. Saraf, P. Patheja, F. Khan, and P. K. Gupta, “Low-level laser therapy as an adjunct to conventional therapy in the treatment of diabetic foot ulcers,” *Lasers in Medical Science*, vol. 32, no. 2, pp. 275–282, 2017.

[10] S. A. Tantawy, W. K. Abdelbasset, D. M. Kamel, and S. M. Alrawaili, “A randomized controlled trial comparing helium-neon laser therapy and infrared laser therapy in patients with diabetic foot ulcer,” *Lasers in Medical Science*, vol. 33, no. 9, pp. 1901–1906, 2018.

[11] E. Merigo, J. P. Rocca, A. Oppici, L. Cella, and C. Fornaini, “At-home laser treatment of oral neuronal disorders: case reports,” *Journal of Clinical and Experimental Dentistry*, vol. 9, no. 4, pp. e595–e598, 2017.

[12] C. Fornaini, A. Pelosi, V. Queirolo, P. Vescovi, and E. Merigo, “The “at-home LLLT” in temporo-mandibular disorders pain control: a pilot study,” *Laser Therapy*, vol. 24, no. 1, pp. 47–52, 2015.

[13] L. Gavish and N. N. Houreld, “Therapeutic efficacy of home-use photobiomodulation devices: a systematic literature review,” *Photobiomodulation, Photomedicine, and Laser Surgery*, vol. 37, no. 1, pp. 4–16, 2019.

[14] A. Amaroli, S. Ravera, F. Baldini, S. Benedicenti, I. Panfoli, and L. Vergani, “Photobiomodulation with 808-nm diode laser light promotes wound healing of human endothelial cells through increased reactive oxygen species production stimulating mitochondrial oxidative phosphorylation,” *Lasers in Medical Science*, vol. 34, no. 3, pp. 495–504, 2019.

[15] E. Everett and N. Mathioudakis, “Update on management of diabetic foot ulcers,” *Annals of the New York Academy of Sciences*, vol. 1411, no. 1, pp. 153–165, 2018.